Kingdon Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Kingdon Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-300,000	Closed	-$3.67M	–	189
2014 Q4	$3.67M	Buy	+300,000	New	+$3.66M	0.16%	118
2014 Q1	–	Sell	-250,000	Closed	-$830K	–	222
2013 Q4	$830K	Hold	250,000	–	–	0.04%	167
2013 Q3	$755K	Sell	250,000 -200,000	-44%	-$1.37M	0.04%	174
2013 Q2	$3.68M	Buy	+450,000	New	+$3.44M	0.22%	120

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kingdon Capital Management's ACHN Position: Q2 2015 in Review

Kingdon Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 291,000 shares — an estimated $2.87M sold.

Kingdon Capital Management first reported a position in ACHN in Q2 2013 and held it in 2 quarters. The position peaked at $2.87M in Q1 2015. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

Kingdon Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Kingdon Capital Management sold 291,000 Achillion Pharmaceuticals shares in Q2 2015, an estimated $2.87M.
Kingdon Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
Kingdon Capital Management's Achillion Pharmaceuticals position peaked at $2.87M in Q1 2015.
158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on Kingdon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.